Related Experiment Video
Updated: May 12, 2025

10:50
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
7.6K
Seronegative Autoimmune Encephalomyelitis with Area Postrema Symptoms.
David Andrew Prentice1, Ravi Ambati2,3, Lay K Kho2,3
1Perron Institute for Neurological and Translational Science, Perth, WA, Australia.
Case Reports in Neurology
|May 8, 2025
Summary
This case study explores a rare encephalomyelitis with area postrema symptoms. Researchers hypothesize tanycytes, glial cells in the area postrema, may be a new target in autoimmune encephalitis.
Area of Science:
- Neuroimmunology
- Neurology
Background:
- Encephalopathy and longitudinally extensive myelitis present diagnostic challenges.
- Area postrema symptoms like intractable hiccoughs can help differentiate diagnoses.
- Neuromyelitis optica spectrum disorders and GFAP autoimmune encephalitis are known causes, but some cases are seronegative.
Observation:
- A previously healthy man in his 70s experienced headache, fever, confusion, seizure, and persistent hiccoughs.
- MRI showed brainstem involvement and extensive transverse myelitis.
- Initial CSF analysis revealed inflammation, but tests for AQP4, MOG, and GFAP antibodies were negative.
Findings:
- The patient showed a weak positive for serum GFAP-IgG after treatment, but CSF remained negative.
- Immunotherapy improved his condition, though significant lower limb weakness persisted.
- This suggests a seronegative encephalomyelitis syndrome with area postrema involvement.
Implications:
- Tanycytes, specialized glial cells in the area postrema, are hypothesized as a potential immune target in GFAP encephalitis.
- This case suggests glial cells beyond astrocytes may be involved in autoimmune neuroinflammation.
- Further research is needed to investigate the role of tanycytes in autoimmune neuroinflammation.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
977
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
977
Myasthenia Gravis: Diagnostic Tests
545
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
545

